
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sonpiretigene Isteparvovec
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Nanoscope Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Verana & Nanoscope Collaborate on Retinitis Pigmentosa Research
Details : The collaboration aims fot the development and commercialization of MCO-010 (sonpiretigene isteparvovec), an optogenetic gene therapy designed to restore vision and potentially slow neurodegeneration.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : Sonpiretigene Isteparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Nanoscope Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
